Literature DB >> 21609839

A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic.

Matthias A Oberli1, Marie-Lyn Hecht, Pascal Bindschädler, Alexander Adibekian, Thomas Adam, Peter H Seeberger.   

Abstract

Nosocomial infections with the Gram-positive pathogen Clostridium difficile pose a major risk for hospitalized patients and result in significant costs to health care systems. Here, we present the chemical synthesis of a PS-II hapten of a cell wall polysaccharide of hypervirulent ribotype 027 of C. difficile. Mice were immunized with a conjugate consisting of the synthetic hexasaccharide and the diphtheria toxoid variant CRM(197). The immunogenicity of the glycan repeating unit was demonstrated by the presence of specific IgG antibodies in the serum of immunized mice. Murine monoclonal antibodies interact with the synthetic hexasaccharide, as determined by microarray analysis. Finally, we found that specific IgA antibodies in the stool of hospital patients infected with C. difficile recognize the synthetic PS-II hexasaccharide hapten.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609839     DOI: 10.1016/j.chembiol.2011.03.009

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  28 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 3.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 4.  Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.

Authors:  Gayatri Vedantam; Andrew Clark; Michele Chu; Rebecca McQuade; Michael Mallozzi; V K Viswanathan
Journal:  Gut Microbes       Date:  2012-03-01

5.  Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.

Authors:  Wenjing Shang; Zhongying Xiao; Zaikuan Yu; Na Wei; Guohui Zhao; Qing Zhang; Mohui Wei; Xuan Wang; Peng George Wang; Tiehai Li
Journal:  Org Biomol Chem       Date:  2015-03-12       Impact factor: 3.876

Review 6.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

Review 7.  Carbohydrate microarrays.

Authors:  Sungjin Park; Jeffrey C Gildersleeve; Ola Blixt; Injae Shin
Journal:  Chem Soc Rev       Date:  2012-11-28       Impact factor: 54.564

8.  Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.

Authors:  Andrew D Cox; Frank St Michael; Annie Aubry; Chantelle M Cairns; Philippa C R Strong; Alexander C Hayes; Susan M Logan
Journal:  Glycoconj J       Date:  2013-08-23       Impact factor: 2.916

Review 9.  Clostridium difficile infection in the twenty-first century.

Authors:  Chandrabali Ghose
Journal:  Emerg Microbes Infect       Date:  2013-09-18       Impact factor: 7.163

10.  Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.

Authors:  Fredy Chaparro-Rojas; Kathleen M Mullane
Journal:  Infect Drug Resist       Date:  2013-06-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.